Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report) and Galapagos (GLPG – Research Report).
Crispr Therapeutics AG (CRSP)
In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Crispr Therapeutics AG, with a price target of $43.00. The company’s shares closed last Monday at $48.59.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $83.87 average price target.
See today’s best-performing stocks on TipRanks >>
Galapagos (GLPG)
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Galapagos today and set a price target of $40.00. The company’s shares closed last Monday at $39.60.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Galapagos with a $41.75 average price target, implying a 7.1% upside from current levels. In a report issued on August 7, RBC Capital also maintained a Hold rating on the stock with a $38.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRSP:
- Crispr Therapeutics price target lowered to $110 from $123 at Chardan
- Crispr Therapeutics reports Q2 EPS (98c), consensus ($2.12)
- CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
- CRSP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Crispr Therapeutics call volume above normal and directionally bullish
